Prudential Financial Inc
Change company Symbol lookup
Select an option...
PRU Prudential Financial Inc
T AT&T Inc
VZ Verizon Communications Inc
BXMT Blackstone Mortgage Trust Inc
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PD PagerDuty Inc

Financials : Insurance | Large Cap Value
Company profile

Prudential Financial, Inc., is a financial services company. The Company, through its subsidiaries, offers a range of financial products and services, which includes life insurance, annuities, retirement-related services, mutual funds and investment management. The Company's operations consists of four divisions, which together encompass seven segments. The U.S. Retirement Solutions and Investment Management division consists of Individual Annuities, Retirement and Asset Management segments. The U.S. Individual Life and Group Insurance division consists of Individual Life and Group Insurance segments. The International Insurance division consists of International Insurance segment. The Closed Block division consists of Closed Block segment. The Company has operations in the United States, Asia, Europe and Latin America.

Day's Change
-1.13 (-1.82%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 1,722,725 shares is on pace to be much greater than PRU's 10-day average volume of 2,512,205 shares.


Gilead to develop immuno-oncology drugs with Arcus

7:33 am ET May 27, 2020 (MarketWatch)

Shares of Gilead Sciences Inc. (GILD) were down 0.4% in premarket trading on Wednesday after the drugmaker said it inked a 10-year deal to develop and commercialize Arcus Biosciences Inc.'s (RCUS) investigational immuno-oncology therapies. Arcus's stock was down 7.5% before the market opened. Gilead will make a $175 million upfront payment and take a $200 million equity stake, and an additional $1.6 billion will be available for milestone payments and R&D funding. Last month people familiar with the matter told Bloomberg News ( that Gilead was considering a stake in Arcus. The deal is expected to close in the third quarter. Since the start of the year, Gilead's stock has gained 12.6%, after a series of rallies spurred by the market response to its COVID-19 treatment remdesivir getting emergency authorization from the Food and Drug Administration. Year-to-date, shares of Arcus have soared 232.1%, and the S&P 500 is down 7.4%.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

May 27, 2020 07:33 ET (11:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.